Biogen : Movement Disorders at Biogen

Movement Disorders at Biogen

Tien Dam, M.D., Head of Movement Disorders

Carole Ho, M.D., Chief Medical Officer & Head of Development, Denali Therapeutics

R&D Day

September 21, 2021

Forward-looking statements

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development

programs, clinical trials, and data readouts and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our and our collaboration partners' products and investigational therapies; the anticipated benefits and potential of investments, collaborations, and business development activities; and our future financial and operating results. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "possible," "prospect," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development

programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives;

difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications;

risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; risks relating to technology failures or breaches; risks relating to management and key personnel changes, including attracting and retaining key personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate

fluctuations; risks relating to investment in our manufacturing capacity; problems with our manufacturing processes; fluctuations in our effective tax rate; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission (SEC).

These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.

2

Biogen has one of the leading movement disorders pipelines

		Pre-R2D	Phase 1	Phase 2	Phase 3
BIIB124 (GABAA modulator SM)*
Essential Tremor
BIIB122 (LRRK2 SM)**
Parkinson's disease
BIIB094 (LRRK2 ASO)#
Parkinson's disease
BIIB118 (CK1 SM)
Parkinson's disease
BIIB101 ( -synuclein ASO)#
Multiple	System Atrophy
⍺
4 Undisclosed programs (multiple modalities)
Parkinson's disease
1 Undisclosed program
Spinocerebellar Ataxia			*collaboration with Sage Therapeutics
				**collaboration with Denali Therapeutics
2 Undisclosed programs (multiple modalities)
		#collaboration with Ionis Pharmaceuticals
Huntington's disease

ASO = antisense oligonucleotide; CK1 = casein kinase 1; GABAA = gamma-aminobutyric acid type A; LRRK2 = leucine rich repeat kinase 2; PAM = positive allosteric modulator; SM = small molecule

3

Highlights on Movement Disorders Portfolio

01	Movement Disorders Pipeline and Strategy
Multi-modality,multi-target approach
02	Advances in Therapies for Parkinson's
Disease
	BIIB122 (DNL 151) - LRRK2 Kinase Inhibitor
	(in collaboration with Denali Therapeutics)
	BIIB094 - LRRK2 ASO
	(in collaboration with Ionis Pharmaceuticals)
	BIIB118 - CK1 Inhibitor
03	Novel Approach to Essential Tremor
BIIB124 (SAGE-324)- GABAA PAM

(in collaboration with Sage Therapeutics)

4

Biogen's R&D strategy in movement disorders

Leverage scientific, clinical, and commercial synergies - and Biogen's multi-modality expertise - to address patient needs

Parkinson's disease:			Atypical Parkinsonism:		Genetically defined
Slow progression and address			Target proteins that form		movement disorders
major untreated symptoms			aggregates in severe, rare
			Parkinsonisms
• Despite dopamine		•	Progressive supranuclear		• Mitigate risk by targeting
replacement therapies, there			palsy (PSP) and Multiple		genetic adjacencies
is no disease-modifying			system atrophy (MSA) are
therapy for Parkinson's			rapidly progressing, fatal
disease			conditions
• Major clinical needs (e.g.,		•	⍺
	Tau and -synuclein
cognitive deficits) remain			compounds have potential
untreated			for PSP and MSA

5